Lymphoma prognostic methods and kits

Abstract

This disclosure describes, in one aspect, a method that, in general, includes analyzing a tumor tissue sample from a subject for expression of at least two biomarkers, wherein a predetermined ratio of expression of the at least two biomarkers identifies the tumor tissue sample as coming from a subject having a particular subtype of lymphoma; and identifying the subject as having a particular subtype of lymphoma.

1 - 25 . (canceled) 
     
     
         26 . A kit for determining prognosis of a subject, the kit comprising:
 reagents for measuring expression of a plurality of predictive coding regions in a sample from the subject, the plurality of predictive coding regions comprising at least one of:
 a combination of CD28 and ABCA5; or 
 a combination of CCDC3 and SMOC2. 
   
     
     
         27 . The kit of  claim 26  wherein the reagents for measuring expression of a plurality of predictive coding regions comprises reagents for performing Northern blotting, nuclease protection assay, DNA microarray, serial analysis of gene expression, quantitative reverse transcription-polymerase chain reaction (RT-PCR), differential-display RT-PCR, massively parallel signature sequencing, or real-time quantitative PCR. 
     
     
         28 . The kit of  claim 26  wherein the reagents for measuring expression of a plurality of predictive coding regions comprises reagents for performing protein expression analysis. 
     
     
         29 - 34 . (canceled)